Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

$IPIX Ongoing Kevetrin Ph 2 ---> A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer

Objective - tumor response to treatment with Kevetrin [ Time Frame: 3 Weeks ]
Number of subjects in each response category (complete response, partial response, stable disease or progressive disease) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

https://clinicaltrials.gov/ct2/show/NCT03042702

Kevetrin making headway. Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer

Unmasked.

Official Title: A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Estimated Study Completion Date: December 31, 2017
Estimated Primary Completion Date: December 31, 2017 (Final data collection date for primary outcome measure)

https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=2